253 related articles for article (PubMed ID: 26699502)
21. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
[TBL] [Abstract][Full Text] [Related]
22. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
23. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.
Weinstein S; Emmanuel R; Jacobi AM; Abraham A; Behlke MA; Sprague AG; Novobrantseva TI; Nagler A; Peer D
PLoS One; 2012; 7(8):e43343. PubMed ID: 22905260
[TBL] [Abstract][Full Text] [Related]
24. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract][Full Text] [Related]
25. Histopathology of mantle cell lymphoma.
Klapper W
Semin Hematol; 2011 Jul; 48(3):148-54. PubMed ID: 21782056
[TBL] [Abstract][Full Text] [Related]
26. Should there be a standard therapy for mantle cell lymphoma?
Smith MR
Future Oncol; 2011 Feb; 7(2):227-37. PubMed ID: 21345142
[TBL] [Abstract][Full Text] [Related]
27. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
28. [Detection of cyclin D1 mRNA by reverse transcription-polymerase chain reaction in paraffin-embedded tissues and its diagnostic significance for mantle cell lymphoma].
Shui RH; Wei YK; Sun MH; Wang J; Shi DR; Zhang TM; Jin AP; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 Aug; 34(8):514-8. PubMed ID: 16383299
[TBL] [Abstract][Full Text] [Related]
29. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
30. JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Su H; Ma X; Huang Y; Han H; Zou Y; Huang W
Int J Clin Exp Pathol; 2015; 8(1):171-83. PubMed ID: 25755704
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells.
Landesman-Milo D; Goldsmith M; Leviatan Ben-Arye S; Witenberg B; Brown E; Leibovitch S; Azriel S; Tabak S; Morad V; Peer D
Cancer Lett; 2013 Jul; 334(2):221-7. PubMed ID: 22935680
[TBL] [Abstract][Full Text] [Related]
32. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell-based therapy for mantle cell lymphoma.
Munger CM; Vose JM; Joshi SS
Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434
[TBL] [Abstract][Full Text] [Related]
34. [In vitro gene silencing by siRNA of cyclin D1 on tongue squamous cell carcinoma cell line resistant to cisplatin].
Zhou XJ; Zhang ZY; Zhang P; Pan HY; Chen WT; Ye DX
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Nov; 41(11):646-9. PubMed ID: 17331354
[TBL] [Abstract][Full Text] [Related]
35. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Tabernero J; Shapiro GI; LoRusso PM; Cervantes A; Schwartz GK; Weiss GJ; Paz-Ares L; Cho DC; Infante JR; Alsina M; Gounder MM; Falzone R; Harrop J; White AC; Toudjarska I; Bumcrot D; Meyers RE; Hinkle G; Svrzikapa N; Hutabarat RM; Clausen VA; Cehelsky J; Nochur SV; Gamba-Vitalo C; Vaishnaw AK; Sah DW; Gollob JA; Burris HA
Cancer Discov; 2013 Apr; 3(4):406-17. PubMed ID: 23358650
[TBL] [Abstract][Full Text] [Related]
36. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1.
Sander B; Flygare J; Porwit-Macdonald A; Smith CI; Emanuelsson E; Kimby E; Liden J; Christensson B
Int J Cancer; 2005 Nov; 117(3):418-30. PubMed ID: 15900590
[TBL] [Abstract][Full Text] [Related]
38. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
39. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Klier M; Anastasov N; Hermann A; Meindl T; Angermeier D; Raffeld M; Fend F; Quintanilla-Martinez L
Leukemia; 2008 Nov; 22(11):2097-105. PubMed ID: 18685613
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
